The Committee for Medicinal Products for Human Use (CHMP), the scientific board of European Medicines Agency, has issued a positive opinion on Samsung Bioepis’ Flixabi for the treatment of ulcerative colitis (UC) and Crohn’s disease, and for rheumatoid arthritis, ankylosing spondylitis, psoriasis, and psoriatic arthritis.
Flixabi (SB2) is a biological product similar to the reference product Remicade (infliximab), and the second anti-TNF-α drug developed by the company receiving a positive opinion for approval in Europe.
The active substance of Flixabi is infliximab, an immunosuppressant. Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of the tumor necrosis factor α (TNFα), but not to lymphotoxin α (TNFβ).
The European Commission (EC) will now review CHMP’s opinion, and issue a final decision concerning marketing authorization for Flixabi. If the EC grants approval, Flixabi will be marketed in the European Union by Biogen as a 100 mg powder concentrate solution for infusion.
“The CHMP’s positive opinion on Flixabi brings us a step closer to broadening affordable, high-quality treatment options for autoimmune patients across Europe,” said Christopher Hansung Ko, president and CEO of Samsung Bioepis in a press release. “We will continue to leverage our strengths in product development and quality assurance, so that we can increase patient access to a wider choice of life-enhancing medications.”
CHMP’s opinion was based on data derived from Phase 1 and 3 clinical trials assessing Flixabi as a biological medicinal product similar to Remicade. Results from the 54-week Phase 3 randomized trial, involving 584 patients with moderate to severe rheumatoid arthritis across 73 sites in 11 countries, found equivalent efficacy and comparable safety.
Samsung Bioepis currently holds a portfolio of 13 biosimilar products, covering the therapeutic areas of oncology, immunology, and diabetes:
- SB4, a biological medicinal product similar to Enbrel (etanercept)
- SB2, a biological medicinal product similar to Remicade (infliximab)
- SB5, a biological medicinal product similar to Humira (adalimumab)
- SB9 (MK-1293), a biological medicinal product similar to Lantus (insulin glargine)
- SB3, a biological medicinal product similar to Herceptin (trastuzumab)
- SB8, a biological medicinal product similar to Avastin (bevacizumab)
Upon approval, Samsung Bioepis’ biosimilar products will be marketed by Biogen and Merck, under commercialization agreements between the companies.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?